Clinical Trial Update: Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia [Phase 1]

View source ↗

Summary

This update reports the completed Phase 1 study assessing safety, tolerability, and pharmacokinetics of SEP-363856 in adults with schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• SEP-363856

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED